Oxazepam
Oxazepam. Intermediate-acting benzodiazepine — direct glucuronidation (no oxidation) makes it the preferred benzodiazepine in elderly and… Oral half-life 5.8 h.
Intermediate-acting benzodiazepine — direct glucuronidation (no oxidation) makes it the preferred benzodiazepine in elderly and hepatic impairment. Active metabolite of diazepam. Slower onset limits acute-anxiety use; better fit for sustained anxiolysis.
PK: THE BEST CONTROL IN ITS GROUP, AND ONLY TWO FIELDS MOVE. F 0.93 is verbatim ("a bioavailability of 92.8%") and V 41 L is verbatim by the registry own weight convention ("volume of distribution at steady-state (Vss) 0.59 l.kg-1"), INTRAVENOUS in the same subjects who took the oral dose, so class 6 is acquitted outright. The half-life was the single inconsistency: that paper reports 6.7 h intravenously and 5.8 h orally and the record stored 8, which made implied clearance 27% low against the paper own figure. A NEAR-MISS IS RECORDED SO NOBODY "CORRECTS" IT BACK: 8 h is within three percent of a real verbatim mean elsewhere in this literature, "longer in females (mean: 9.7 hr) than in males (7.8 hr)", and within one percent of an elderly median of 8.1 h — it is defensible literature, simply not this citation number. ka 0.5 is REMOVED rather than replaced: it implied a 4.24 h peak against this paper own "the peak plasma level was reached in 1.7 to 2.8 h", both available Tmax figures are RANGES so a midpoint is barred, and deleting lands on the solver default of 1.0, which puts the peak at 2.41 h — inside both published ranges. It was also not a default to begin with; the solver default is 1.0, so 0.5 was entered deliberately and unsourced.
Pharmacokinetics
- Oral — t½ 5.8 h · F 93% · Vd 41 L
Sources: PMID:3197746